

Discovery of small molecular G9a inhibitor leads in advanced solid tumor: tumor growth inhibition and anti-cancer immunity activation

Asan Medical Center



| ONCOLOGY | Lead |
|--------------------------|--|
| Product Type | Small Molecule |
| Indication | Refractory advanced solid tumor |
| Target | G9a (Histone methyl transferase 2, EHMT2) |
| MoA(Mechanism of Action) | Inhibition of G9a leads to (1) Growth inhibition of tumor and cancer stem cells (2) Potentiation of anti-cancer immunity |
| Competitiveness | First in class G9a inhibitor can be used in combination treatment with immune checkpoint inhibitors. |
| Development Stage | Lead |
| Route of Administration | IV or PO |